These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30711279)

  • 21. Sex Disparities After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer.
    Rowse PG; Jaroszewski DE; Thomas M; Harold K; Harmsen WS; Shen KR
    Ann Thorac Surg; 2017 Oct; 104(4):1147-1152. PubMed ID: 28842111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
    McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 24. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
    Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
    Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
    Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
    Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
    Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
    Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
    Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
    Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
    Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Kersting S; Konopke R; Dittert D; Distler M; Rückert F; Gastmeier J; Baretton GB; Saeger HD
    J Gastroenterol Hepatol; 2009 May; 24(5):886-95. PubMed ID: 19655439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.